These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Key Takeaways New data show that GLP1-RA meds like semaglutide can help slow the progression of chronic kidney diseaseThe ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s disease ...

The GLP-1 drug, exenatide ... to patients affected by Parkinson's disease and the Parkinson's disease research community." GLP-1 drugs—such as semaglutide (Wegovy) and Ozempic—have become ...

Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in ...

“In addition, randomized clinical trials show that the GLP-1 meds are associated with significant benefits including decreasing risk for cardiovascular disease, kidney disease, sleep ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...